Alice S. Mims

机构：The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Wexner Medical Center, Ohio State University Hospital, The Ohio State University · ORCID：0000-0002-8971-2199

发表论文 458 篇 · 总被引 7104 次 · h-index 39

代表论文

• RAS pathway activation and microenvironmental adaptation as hallmarks of myeloid sarcoma (2026 · Blood Cancer Discovery · 被引 1)
• Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) (2026 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 1)
• Clinical outcomes of older patients with NPM1 -mutated or KMT2A- rearranged AML before menin inhibitors: a Beat AML report (2026 · Blood Advances · 被引 1)
• Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial (2025 · Cancers · 被引 1)
• Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. (2026 · UNC Libraries)
• OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML (2026 · Blood)